GlassScriptPhysician profile
Elisabeth A Sciotto
NPI 1699027565
$3,206.52
in general payments reported to CMS, 2019-2025
35 companies · $1,484 in 2025
The $1,484 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $152 · 2022: $421 · 2023: $594 · 2024: $555 · 2025: $1,484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,586 · Education: $46.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,586.09 |
| Education | $46.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $694.44 | 2022-2025 | |
| Pfizer INC. | $402.83 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $355.89 | 2021-2025 | Ingrezza |
| Alexion Pharmaceuticals, INC. | $251.15 | 2025 | Ultomiris |
| Jazz Pharmaceuticals INC. | $214.94 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $157.91 | 2022-2023 | |
| Argenx US, INC. | $122.11 | 2024 | Vyvgart Hytrulo |
| Axsome Therapeutics, INC. | $107.05 | 2025 | Symbravo |
| Amgen INC. | $106.13 | 2023-2025 | Uplizna, Repatha |
| Astrazeneca Pharmaceuticals LP | $75.22 | 2022-2023 | Farxiga |
| Livanova USA, INC. | $64.81 | 2025 | Vns Therapy |
| Lundbeck LLC | $59.47 | 2024-2025 | Vyepti |
| Tg Therapeutics, INC. | $51.77 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $40.11 | 2022-2023 | Rexulti, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $35.76 | 2025 | Ponvory |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $34.31 | 2025 | |
| Ucb, INC. | $33.98 | 2025 | Rystiggo |
| Sk Life Science, INC. | $27.21 | 2024 | Xcopri |
| Genentech USA, INC. | $26.61 | 2025 | Ocrevus Zunovo |
| Alkermes, INC. | $25.59 | 2024 | Aristada, Lybalvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.33 | 2023 | Tradjenta, Synjardy |
| Sobi, INC | $25.28 | 2022 | |
| Glaxosmithkline, LLC. | $25.15 | 2025 | Arexvy, Shingrix |
| Ge Healthcare | $24.75 | 2025 | |
| Mallinckrodt Hospital Products INC. | $23.15 | 2025 | Acthar |
| Ani Pharmaceuticals, INC. | $22.27 | 2025 | Purified Cortrophin Gel |
| Springworks Therapeutics, INC. | $22.03 | 2025 | Gomekli |
| Seqirus USA INC | $21.52 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Novo Nordisk INC | $21.33 | 2024 | Rybelsus, Ozempic |
| Exact Sciences Corporation | $21.32 | 2023 | Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $19.01 | 2023 | Qelbree |
| Lilly USA, LLC | $18.98 | 2022 | |
| Acadia Pharmaceuticals INC | $17.05 | 2025 | Nuplazid |
| Horizon Therapeutics Plc | $16.90 | 2023 | Krystexxa |
| Teva Pharmaceuticals USA, INC. | $15.16 | 2023 | Austedo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elisabeth Sciotto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.